Company intelligence / Profile preview

Cassava Sciences

Austin, Texas, United States

Ownership: Public · SAVA
Employees: ~25
Development stage: Phase 3

Overview

Simufilam, the company’s lead oral small molecule targeting filamin A for Alzheimer’s disease, failed to show clinical benefit in two large Phase 3 trials (RETHINK-ALZ and REFOCUS-ALZ). Both studies did not meet their primary endpoints and were discontinued in late 2024. The company has since ended its Alzheimer’s program but is exploring simufilam for other central nervous system disorders such as TSC-related epilepsy[2][4][6].

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

7 assets

Remoxy

6 more assets in the full pipeline.

Request access →

Partnerships

No major pharma or biotech partnerships disclosed publicly as of May 2025.

Financials

Market cap: $63.8M
Total revenue: $0
Enterprise value: $-18.9M

Beyond the preview

Go deeper on Cassava Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cassava Sciences.

Explore the full profile